Literature DB >> 16258412

[Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) and their role in immunoregulation and inflammation control].

Milena Sokołowska1, Marek L Kowalski, Rafał Pawliczak.   

Abstract

Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) are members of the nuclear receptor superfamily containing transcription factors regulating gene expression. PPAR-gamma have attracted attention so far as key factors in adipogenesis, lipid metabolism, insulin sensitivity, and apoptosis. Recently, growing evidence points to their implication in the regulation of the immune response, particularly in inflammation control. Not only are PPAR-gamma found in various structures of the immune system, but many inflammatory mediators, such as arachidonic acid and its metabolites, also act as potent and specific ligands of them. Inflammation is the basis of the pathogeneses of such chronic diseases as bronchial asthma, atherosclerosis, rheumatoid arthritis, and chronic inflammatory bowel diseases. The causative relationship between PPAR-gamma activity and the pathogeneses of these inflammatory disorders has been found in specific animal models. Moreover, PPAR-gamma agonists have been shown to act as potent anti-inflammatory agents. Thus, PPAR-gamma can serve as potential therapeutic targets in the treatment of inflammation. The aim of this paper is to present the characteristics of PPAR-gamma regarding their gene and protein structures, ligand selectivity, mechanisms of action, and target genes. The review highlights the roles that PPAR-gamma play in inflammation and immune responses. Particular emphasis is focused on their roles in asthma, atheroclerosis, rheumatoid arthritis and chronic inflammatory bowel diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258412

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  8 in total

1.  Influence of ciglitazone on A549 cells growth in vitro and in vivo and mechanism.

Authors:  Wanguang Zhang; Huilan Zhang; Lihua Xing
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

2.  Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in PPARG Expanding the Spectrum of Disease-Causing Alterations in FPLD3.

Authors:  Lena Rutkowska; Dominik Salachna; Krzysztof Lewandowski; Andrzej Lewiński; Agnieszka Gach
Journal:  Diagnostics (Basel)       Date:  2022-04-30

3.  Activated and inactivated PPARs-γ modulate experimentally induced colitis in rats.

Authors:  Krzysztof Celinski; Tomasz Dworzanski; Agnieszka Korolczuk; Maria Slomka; Sebastian Radej; Halina Cichoz-Lach; Agnieszka Madro
Journal:  Med Sci Monit       Date:  2011-04

Review 4.  Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases.

Authors:  Su Zhang; Hongwei Gu; Nan Hu
Journal:  J Ophthalmol       Date:  2015-06-04       Impact factor: 1.909

5.  Fatty Acids of CLA-Enriched Egg Yolks Can Induce Transcriptional Activation of Peroxisome Proliferator-Activated Receptors in MCF-7 Breast Cancer Cells.

Authors:  Aneta A Koronowicz; Paula Banks; Adam Master; Dominik Domagała; Ewelina Piasna-Słupecka; Mariola Drozdowska; Elżbieta Sikora; Piotr Laidler
Journal:  PPAR Res       Date:  2017-03-26       Impact factor: 4.964

6.  Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.

Authors:  Satya Prakash; Aleksandra Malgorzata Urbanska
Journal:  Biologics       Date:  2008-09

7.  Comparison of selected gene expression profiles in sensitive and resistant cancer cells treated with doxorubicin and Selol.

Authors:  Jadwiga Dudkiewicz-Wilczyńska; Agnieszka Grabowska; Iza Książek; Karolina Sitarz; Piotr Suchocki; Elżbieta Anuszewska
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03

8.  Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model.

Authors:  Mashal M Almutairi; Wael A Alanazi; Musaad A Alshammari; Moureq Rashed Alotaibi; Ali R Alhoshani; Salim Salah Al-Rejaie; Mohamed M Hafez; Othman A Al-Shabanah
Journal:  BMC Complement Altern Med       Date:  2017-09-29       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.